ClinicalTrials.gg
RecruitingNCT05829655Updated Jun 23, 2026

Measuring Acute Drug Demand in Humans

An Early Phase 1 interventional study of Drug A (Blinded Drug) and Drug B (Blinded Drug) in Opioid Use Disorder and Opioid Dependence, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by University of Maryland, Baltimore · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore — 6 open to participants now, 8 under way, 2 of them phase 3. Opioid-Related Disorders · University of Maryland, Baltimore.

Planned enrollment
4th of 15
75 · median 50
Started
2023
with 1 other
Phase 1
2 of 16
1 open now
Registered
10th of 16
by date

Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 10th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

6 of the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

Read the detailed description

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs. Suvorexant is not approved as a treatment to reduce drug use but is approved by the Food and Drug Administration (FDA) to treat insomnia (trouble falling asleep or staying asleep). This study consists of a screening visit and an approximate 14 to 16 day inpatient (overnight) stay at the University of Maryland, Baltimore. Participants will be stabilized on hydromorphone, randomly assigned to receive either suvorexant or placebo, and complete 5 experimental sessions that include taking blinded study medications.

03

Conditions studied

  • Opioid Use Disorder
  • Opioid Dependence
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years old
  • Meets Diagnostic and Statistical Manual-5 criteria for Opioid Use Disorder (OUD) (moderate or severe)
  • Lifetime substance use history criterion [blinded]
  • Medically cleared to take suvorexant and blinded study medications
  • Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding
  • Seeking opioid use treatment
  • Significant mental health or physical disorder that is expected to interfere with study participation as assessed by the study physicians or medical staff
  • Known or allergies to suvorexant and/or the blinded study medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Suvorexant (20mg/day)

    Double blind administration of suvorexant once per day during residential stay until discharge

    Drug: Drug A (Blinded Drug) · Drug: Drug B (Blinded Drug) · Drug: Drug C (Blinded Drug) · Drug: Drug D (Blinded Drug) · Drug: Suvorexant (20mg/day)

  • Placebo comparator
    Placebo

    Double blind administration of placebo once per day during residential stay until discharge

    Drug: Drug A (Blinded Drug) · Drug: Drug B (Blinded Drug) · Drug: Drug C (Blinded Drug) · Drug: Drug D (Blinded Drug) · Drug: Placebo

Interventions

  • DrugDrug A (Blinded Drug)

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • DrugDrug B (Blinded Drug)

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • DrugDrug C (Blinded Drug)

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • DrugDrug D (Blinded Drug)

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • DrugSuvorexant (20mg/day)

    Drug page: SuvorexantStudies of SuvorexantSuvorexant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Double blind administration of suvorexant once per day during residential stay until discharge.

  • DrugPlacebo

    Double blind administration of placebo once per day during residential stay until discharge.

06

What researchers measure

Primary outcomes

  1. Demand Intensity

    Consumption of blinded drug at unconstrained price as measured by an incentivized demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate more drug consumption at unconstrained price (a worse outcome).

    Time frame: Upon completion of experimental session (~8 hours post drug administration)

  2. Demand Elasticity

    Changes in blinded drug consumption with changes in price as measured by an incentivized demand task. There is no minimum or maximum value. Higher scores indicate greater drug price sensitivity (a better outcome).

    Time frame: Upon completion of experimental session (~8 hours post drug administration)

  3. Cross-Price Elasticity

    Change in consumption of price-fixed good based on change in price of price varying good. Positive values indicate a substitute, negative values indicate a complement, and zero values indicate an independent commodity.

    Time frame: After Experimental Session 4

Secondary outcomes

  1. Total Mean Sleep Time

    Mean total number of minutes slept per night as measured by actigraphy and self-reported sleep diary. Mean total sleep time will be collected daily.

    Time frame: Through study completion, up to two weeks

07

Study locations

1 of 1 sites recruiting
  • General Clinical Research Center
    Baltimore, Maryland 21201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jan 2028, 52 months after the start.

Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 52 months is above that.

Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
Apr 26, 2023
StartActual
Aug 8, 2023
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05829655
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
Aug 8, 2023
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Justin Strickland, PhD
Contact
jstrickland@som.umaryland.edu
667-354-3516
Justin Strickland, PhD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion